• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Updated guidelines for management of sickle cell disease released

byJohn PrendergassandPriyanka Vedak
September 9, 2014
in Chronic Disease, Pediatrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Strong recommendations based on high-quality evidence are made supporting the referral of children with abnormal transcranial Doppler velocity to stroke-prevention specialists, with additional strong recommendations for simple or exchange blood transfusion in this cohort.

2. Strong recommendations based on high-quality evidence are made for the prompt use of parenteral opioids in adults and children with painful vasoocclusive crises. A consensus statement based on panel expertise was made to utilize sickle cell disease-specific or individualized pain management protocols created by the patient’s sickle cell physician.

3. Strong recommendations based on high-quality evidence are made for the use of hydroxyurea therapy in adults experiencing three or more pain crises (of moderate or severe nature) in a given year. Hydroxyurea therapy is strongly recommended based on high quality evidence in all infants (9 months and older), children, and adolescents with sickle cell anemia so as to reduce the risk of sickle cell-related complications.

Statement Rundown: Sickle cell disease (SCD) affects close to 100,000 individuals in the United States and is associated with organ damage, stroke, skin ulceration, vasoocclusive crises, and avascular necrosis. This article is a summary of recommendations made by the National Heart, Lung, and Blood Institute (NHLBI) expert panel on preventative measures and acute and chronic care for sickle cell disease patients.

These recommendations represent the first updated guidelines in 10 years and utilize a reader-friendly presentation in demonstrating both the strength of recommendation and the quality of evidence on which it is based. However, the formulation of these guidelines did overlook a few of the tips for high-quality guideline construction offered by the Institute of Medicine. These discrepancies include the absence of endorsement by all professional societies with expertise in SCD-related complications and the absence of a patient representative on the guideline construction panel. Moreover, given the absence of robust clinical trial data on the treatment of sickle cell disease, many recommendations are based on lower-quality evidence. Nevertheless, these guidelines impart a number of strong recommendations based on high-quality evidence that will aid in the management of this condition.

Click to read the study, published today in JAMA

Click to read the accompanying editorial, published today in JAMA

RELATED REPORTS

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

#VisualAbstract: Moderate-dose hydroxyurea does not decrease stroke incidence but may lower hospitalization rates in children with sickle cell anaemia, compared to low-dose hydroxyurea

#VisualAbstract ESCORT-HU highlights the real-life positive benefit-to-risk ratio of hydroxyurea in patients with sickle cell disease

Relevant Reading: US Centers for Disease Control and Prevention. Sickle cell disease: data and statistics

More from this author: Reducing surgical complications may increase costs,Protected sleep periods improve intern alertness and sleep duration,ADHD medication decreases rates of criminality in ADHD patients,Low dose aspirin shows net clinical benefit in patients with first unprovoked venous thromboembolism, Rare TREM-2 mutation implicated in Alzheimer’s Disease

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: sickle cell anemia
Previous Post

Key drugs reduce fracture risk in osteoporosis

Next Post

Dementia patients frequently on medications with minimal benefit

RelatedReports

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia
StudyGraphics

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

May 4, 2022
#VisualAbstract: Moderate-dose hydroxyurea does not decrease stroke incidence but may lower hospitalization rates in children with sickle cell anaemia, compared to low-dose hydroxyurea
StudyGraphics

#VisualAbstract: Moderate-dose hydroxyurea does not decrease stroke incidence but may lower hospitalization rates in children with sickle cell anaemia, compared to low-dose hydroxyurea

January 13, 2022
#VisualAbstract ESCORT-HU highlights the real-life positive benefit-to-risk ratio of hydroxyurea in patients with sickle cell disease
StudyGraphics

#VisualAbstract ESCORT-HU highlights the real-life positive benefit-to-risk ratio of hydroxyurea in patients with sickle cell disease

October 8, 2021
#VisualAbstract: Association of Matched Sibling Donor Hematopoietic Stem Cell Transplantation With Transcranial Doppler Velocities in Children With Sickle Cell Anemia
StudyGraphics

#VisualAbstract: Association of Matched Sibling Donor Hematopoietic Stem Cell Transplantation With Transcranial Doppler Velocities in Children With Sickle Cell Anemia

September 6, 2020
Next Post
Cost-related medication nonadherence associated with increased ED utilization

Dementia patients frequently on medications with minimal benefit

No obesity paradox found between BMI, stroke, and death

Conclusions can change following reanalysis of randomized clinical trial data

Dual PDE3/PDE4 inhibitor may be effective treatment for asthma and COPD

Paradoxical response to beta-2 agonists found in African-Americans, linked to morbidity

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Low-dose pirfenidone may be noninferior to standard dosing in patients with idiopathic pulmonary fibrosis
  • Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease
  • College campus monkeypox outbreaks can be controlled with timely detection and isolation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options